This study investigated the effects of blood collection tube type (EDTA, PAXgene or Norgen), processing delays (< 4 h versus > 4 h), and patient condition (gender, age, BMI, health status and exercise) on cell-free DNA (cfDNA) fragmentation patterns.
The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation.
van der Pol Y, Moldovan N, Verkuijlen S, Ramaker J, Boers D, Onstenk W, de Rooij J, Bahce I, Pegtel DM, Mouliere F
Purpose
Conclusion
cfDNA concentration, tumor fraction, and fragment size distribution were unaffected by the type of tube used during blood collection, although the proportion of fragments of specific sizes did differ slightly. While there was no difference in the chromosome arm fragmentation profile or fragment end diversity, specimens from healthy patients clustered separately by collection site. . The proportion of fragments that were 100-150 bp in length and fragmentation end diversity (Shannon entropy index) were comparable among specimens for which processing time was not recorded and those processed in <4 h or >4 h. However, minor significant differences in fragmentation of chromosomes 5 and 11 were found between specimens processed in <4 h and those processed after a delay >4 h.
Plasma from males had a higher proportion of fragments between 100 and 150 bp in length than female patients but no effect of patient age, body mass index, presence of a non-cancer pathology, or medication use was observed. While no individual chromosome displayed differences in fragmentation patterns between specimens from males and females, minor differences in fragmentation of individual chromosomes were found based on patient age, medication use, health status and exercise status.
Studies (3)
Purpose
This study compared cfDNA concentrations and fragmentation among case-matched blood specimens collected in EDTA and PAXgene tubes from healthy patients and lung cancer patients at one center and between matched specimens from healthy patients collected in EDTA and Norgen tubes at a second center. Blood was collected from each patient (five healthy patients and six patients with lung cancer) into an EDTA tube and PAXgene tube. At a different center, case-matched blood specimens were collected from each patient (five additional healthy patients) into an EDTA tube and a Norgen tube. Plasma was isolated by centrifugation at 900 g for 7 min followed by 2500 g for 10 min within 5.5 h of blood draw. Plasma was aliquoted and stored at -80°C. cfDNA was isolated using the QIAsymphony Circulating DNA Kit and cfDNA concentration was quantified using the Cell-free DNA ScreenTape Analysis assay on a Agilent 4200 TapeStation System. Sequencing libraries were prepared using the ThruPLEXVR Plasma-seq Kit and were 150 bp pair-end sequenced on a Illumina NovaSeq 6000. Copy number analysis was performed using the ichorCNA software and cfDNA fragment size analysis was analyzed using the Picard InsertSizeMetrics.
Summary of Findings
In healthy donors, plasma from PAXgene tubes and Norgen tubes had cfDNA concentrations that were comparable to case-matched EDTA plasma; in lung cancer patients, case-matched plasma from PAXgene tubes and EDTA tubes had comparable cfDNA concentrations. Similarly, the tumor fraction was comparable between case-matched specimens, regardless of blood collection tube type. The fragment size distribution had a mode of approximately 167 bp and a comparable proportion of fragments that were 40-150 bp in length, regardless of collection tube type, but EDTA plasma had a higher proportion of fragments that were 60-90 bp in length than case-matched PAXgene plasma (P<0.05, both) and 270, 300, 330, 360 and 390 bp fragments than Norgen plasma (all P<0.01, except 390 bp P<0.05). There were no differences in the chromosome arm fragmentation profiles among the different tube types and specimens mostly clustered by patient. However, clustering segregated patients by collection site. Fragment end analysis showed the expected overrepresentation of CCA, CCT and CCC but there was no difference in fragment end diversity between specimens from healthy patients collected in EDTA tubes and PAXgene or Norgen tubes, nor between specimens from patients with lung cancer collected in EDTA and PAXgene tubes. Interestingly, clustering based on fragment end analysis also resulted in separate clustering of specimens from healthy individuals collected in EDTA tubes at the two different collection sites.
Biospecimens
FluidPlasmaPreservation Types
FrozenPAXgeneDiagnoses
NeoplasticCarcinomaNormalPlatforms
DNAAutomated electrophoresis/BioanalyzerDNANext generation sequencingPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Healthy patientLung cancer patientBiospecimen Acquisition Locale of biospecimen collection Two centers comparedBiospecimen Acquisition Type of collection container/solution EDTA tubeNorgen tubePAXgene tube
Purpose
This study compared cfDNA fragmentation among EDTA plasma specimens from healthy patients subjected to different delays to centrifugation. Plasma was isolated from EDTA blood by centrifugation at 900 g for 7 min followed by 2500 g for 10 min within 4 h of venipuncture (20 patients, 155-232 min), >4 h after venipuncture (9 patients, 240-315 min), or an unspecified time after venipuncture (13 patients). Plasma was aliquoted and stored at -80°C. cfDNA was isolated using the QIAsymphony Circulating DNA Kit and cfDNA concentration quantified using the Cell-free DNA ScreenTape Analysis assay on an Agilent 4200 TapeStation System. Sequencing libraries were prepared using the ThruPLEXVR Plasma-seq Kit and were 150 bp pair-end sequenced on a Illumina NovaSeq 6000. Copy number analysis was performed using the ichorCNA software and cfDNA fragment size was analyzed using the Picard InsertSizeMetrics software.
Summary of Findings
The proportion of fragments that were 100-150 bp in length and fragmentation end diversity (Shannon entropy index) were comparable among specimens for which processing time was not recorded and those processed in <4h or >4 h. However, minor significant differences in fragmentation of chromosome 5 and 11 were found between specimens processed in <4 h and those processed after a delay >4 h (P=0.018 and P=0.011, respectively).
Biospecimens
FluidPlasmaFluidBloodPreservation Types
FrozenDiagnoses
NormalPlatforms
DNANext generation sequencingPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Aliquots and Components Centrifugation Centrifugation delays investigatedStorage Time at room temperature <4 h>4 hUnspecified
Purpose
The purpose of this study was to investigate if patient age, gender, body mass index (BMI), medication use, exercise and presence of non-cancer pathologies affect cfDNA fragmentation. Blood was collected from 42 patients (13 male, 29 female) that were between 26- and 54 years of age with a BMI within the range of 16.5-33.9. Of the 42 patients blood was collected from, 8 had a reported pathological condition (celiac disease, unspecified pulmonary condition, 21-hydroxylase deficiency, bronchiectasis, chronic lyphocytic thyroiditis with hypertension, multiple sclerosis, allergies, and unspecified neurological condition). Patient medicine usage, exercise and alcohol usage were also recorded. Plasma was isolated from EDTA blood by centrifugation at 900 g for 7 min followed by 2500 g for 10 min within 5.5 h of venipuncture. Plasma was aliquoted and stored at -80°C. cfDNA was isolated using the QIAsymphony Circulating DNA Kit and cfDNA concentration was quantified using the Cell-free DNA ScreenTape Analysis assay on an Agilent 4200 TapeStation System. Sequencing libraries were prepared using the ThruPLEXVR Plasma-seq Kit and were 150 bp pair-end sequenced on a Illumina NovaSeq 6000 machine. Copy number analysis was performed using the ichorCNA software and cfDNA fragment size was analyzed using the Picard InsertSizeMetrics software.
Summary of Findings
Plasma from males had a higher proportion of fragments that were 100-150 bp in length compared to female patients (P=0.026), but no effect of patient age, body mass index, presence of a non-cancer pathology, or medication use was found. Interestingly, while no individual chromosome displayed differences in fragmentation patterns between specimens from males and females, minor differences in fragmentation of specific chromosomes were observed for the following comparisons: chromosome 13 between patients taking medication and those not taking medication, chromosomes 13 and 22 between specimens from patients <40 years versus those >40 years of age, chromosome 8 between patients with a non-cancer pathology and those with no reported pathologies, and chromosome 20 between patients that exercised and those that did not (P<0.05, for all). Fragment end diversity was unaffected by patient age, BMI, gender, presence of non-cancer pathologies, or medication use.
Biospecimens
FluidBloodFluidPlasmaPreservation Types
FrozenDiagnoses
Other diagnosesNormalMultiple SclerosisPlatforms
DNANext generation sequencingPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition A non-cancer pathologyHealthyPreaquisition Other drugs No medicationsOne medicationPreaquisition Patient age < 40 years> 40 yearsPreaquisition Patient body mass index 16.5-33.5Normal weightOverweightUnderweightPreaquisition Patient gender FemaleMale